MedTrace Logo

Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients

NCT04094129 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-02-13

No results posted yet for this study

Summary

The present studies demonstrated that pro-inflammation, systemic oxidative stress and dysfunction in the brain-gut microbiota axis were involved in Alzheimer's disease (AD) pathogenesis. These results implied the decreased regulation of inflammation-associated risk and microbiota in AD patients could provide the novel strategies for combating the disease. This study was designed to assess the addition of Wismemo in treatment of cholinesterase inhibitors (such as donepezil, rivastigmine, galantamine) in the AD patients.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Wismemo

Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.

DIETARY_SUPPLEMENT

Placebo

placebo

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • GenMont Biotech Incorporation

    lead INDUSTRY

Principal Investigators

  • Nai-Ching Chen, M.D. · Chang Gung Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-02-11
Completion
2020-02-11

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04094129 on ClinicalTrials.gov